Detail page

Knowledge Web

Person

Volkmar Müller (1967-)

Gynäkologe

Name	Volkmar Müller
Time	1967- (Date of birth and death)
Place	Deutschland
Gender	männlich
Academic degree	Prof. Dr. med.
Profession	Gynäkologe (characteristic profession) Arzt
Related	Universitätsklinikum Hamburg-Eppendorf
Further information	Diss. Fachbereich Medizin; Habil. 2007 Univ. Hamburg, Medizinische Fak., Zentrum für Operative Medizin, Klinik und Poliklinik für Gynäkologie, Geschäftsführender Oberarzt und Leiter konservative gynäkologische Onkologie
Record type	Person
GND-Identifier	12133497X
Record ID	12133497X
Involved in show all Discussion of ABC7 Consensus and German Recommendations Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2024 ABC7 Consensus: Assessment by a German Group of Experts Update Mammakarzinom 2024 Teil 1 – Expertenmeinungen zu Brustkrebs in fortgeschrittenen Krankheitsstadien = Update breast cancer 2024 part 1 – expert opinion on advanced breast cancer Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer – Controversies and Standards in Healthcare Systemic therapy of premenopausal patients with early stage hormone receptor-positive, HER2-negative breast cancer – controversies and standards in healthcare Systemic therapy of premenopausal patients with early stage hormone receptor-positive, HER2-negative breast cancer: controversies and standards in healthcare Update Mammakarzinom 2022 Teil 2 – Brustkrebs in fortgeschrittenen Krankheitsstadien Advanced Breast Cancer : AGO Recommendations 2022 – Focus on ABC6 Consensus Update Breast Cancer 2022 Part 2 – Advanced Stage Breast Cancer Practice-Changing Perspectives regarding Systemic Therapy in Early Breast Cancer: Opinions of German Experts regarding the 17th St. Gallen International Consensus Conference ABC6 Consensus: Assessment by a Group of German Experts Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics – a retrospective analysis of a real world registry Update breast cancer 2022 part 2 – advanced stage breast cancer Update Breast Cancer 2022 Part 2 – Advanced Stage Breast Cancer Correction to: TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021 AGO recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer : update 2021 CD74 and CD44 expression on CTCs in cancer patients with brain metastasis Correction to: TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer Correction to: TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer Predicting prognosis of breast cancer patients with brain metastases in the BMBC registry - comparison of three different GPA prognostic scores Predicting Prognosis of Breast Cancer Patients with Brain Metastases in the BMBC Registry—Comparison of Three Different GPA Prognostic Scores Referenz Gynäkologie TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer ABC5 International Consensus Conference on Advanced Breast Cancer, Lisbon, 16 November 2019 : Commentary by the German panel of experts on the ABC5 voting results Update Breast Cancer 2020 Part 2 – Advanced Breast Cancer: New Treatments and Implementation of Therapies with Companion Diagnostics AGO recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer: update 2020 AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2020 Characteristics and clinical outcome of breast cancer patients with asymptomatic brain metastases Onkologisches Outcome von Patientinnen mit (low-risk) Endometriumkarzinom nach Laparotomie vs. minimal invasiver Hysterektomie : eine retrospektive Analyse Sexual behaviour, desire and psychosexual experience in gynephilic and androphilic trans women : a cross-sectional multi-centre study Clinical relevance of collagen protein degradation markers c3m and c4m in the serum of breast cancer patients treated with neoadjuvant therapy in the geparquinto trial Zusätzlicher Nutzen einer Ganzhirnbestrahlung nach chirurgischer Resektion bzw. stereotaktischer Radiotherapie von Hirnmetastasen bei Patientinnen mit Mammakarzinom Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study Update Breast Cancer 2018 (Part 4) – Genomics, Individualized Medicine and Immune Therapies – in the Middle of a New Era: Treatment Strategies for Advanced Breast Cancer Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study Nukleäre p53 Akkumulation : klinische Relevanz und Interaktion mit anderen etablierten und potentiellen Prognose-Parametern beim Mammakarzinom Update breast cancer 2018 (part 4) – genomics, individualized medicine and immune therapies – in the middle of a new era : treatment strategies for advanced breast cancer Update Mammakarzinom 2018 (Teil 4) – Genomforschung, individualisierte Medizin und Immuntherapien – mitten in einer neuen Ära : Therapie des fortgeschrittenen Mammakarzinoms Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus : Spectrum of Opinion of German Specialists at the 15th International St. Gallen Breast Cancer Conference (Vienna 2017) AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2017 Stellenwert der Präparatradiographie in der brusterhaltenden Therapie des Duktalen Carcinoma in Situ (DCIS) Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer – results from the HER-OS patient registry Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer – results from the HER-OS patient registry Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers AGO Recommendations for Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2013 AGO Recommendations for Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2013 Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study Relevance of activated leukocyte cell adhesion molecule (ALCAM) in tumor tissue and sera of cervical cancer patients Relevance of PTEN loss in brain metastasis formation in breast cancer patients A clinically relevant gene signature in triple negative and basal-like breast cancer Prognostic impact of circulating tumor cells assessed with the CellSearch System and AdnaTest Breast in metastatic breast cancer patients: the DETECT study Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer A clinically relevant gene signature in triple negative and basal-like breast cancer Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer

Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

Katalog der Deutschen Nationalbibliothek

Volkmar Müller (1967-)

Discussion of ABC7 Consensus and German Recommendations

Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2024

ABC7 Consensus: Assessment by a German Group of Experts

Update Mammakarzinom 2024 Teil 1 – Expertenmeinungen zu Brustkrebs in fortgeschrittenen Krankheitsstadien = Update breast cancer 2024 part 1 – expert opinion on advanced breast cancer

Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer – Controversies and Standards in Healthcare

Systemic therapy of premenopausal patients with early stage hormone receptor-positive, HER2-negative breast cancer – controversies and standards in healthcare

Systemic therapy of premenopausal patients with early stage hormone receptor-positive, HER2-negative breast cancer: controversies and standards in healthcare

Update Mammakarzinom 2022 Teil 2 – Brustkrebs in fortgeschrittenen Krankheitsstadien

Advanced Breast Cancer : AGO Recommendations 2022 – Focus on ABC6 Consensus

Update Breast Cancer 2022 Part 2 – Advanced Stage Breast Cancer

Practice-Changing Perspectives regarding Systemic Therapy in Early Breast Cancer: Opinions of German Experts regarding the 17th St. Gallen International Consensus Conference

ABC6 Consensus: Assessment by a Group of German Experts

Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics – a retrospective analysis of a real world registry

Update breast cancer 2022 part 2 – advanced stage breast cancer

Update Breast Cancer 2022 Part 2 – Advanced Stage Breast Cancer

Correction to: TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer

TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer

AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021

AGO recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer : update 2021

CD74 and CD44 expression on CTCs in cancer patients with brain metastasis

Correction to: TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer

Correction to: TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer

Predicting prognosis of breast cancer patients with brain metastases in the BMBC registry - comparison of three different GPA prognostic scores

Predicting Prognosis of Breast Cancer Patients with Brain Metastases in the BMBC Registry—Comparison of Three Different GPA Prognostic Scores

Referenz Gynäkologie

TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer

TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer

TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer

ABC5 International Consensus Conference on Advanced Breast Cancer, Lisbon, 16 November 2019 : Commentary by the German panel of experts on the ABC5 voting results

Update Breast Cancer 2020 Part 2 – Advanced Breast Cancer: New Treatments and Implementation of Therapies with Companion Diagnostics

AGO recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer: update 2020

AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2020

Characteristics and clinical outcome of breast cancer patients with asymptomatic brain metastases

Onkologisches Outcome von Patientinnen mit (low-risk) Endometriumkarzinom nach Laparotomie vs. minimal invasiver Hysterektomie : eine retrospektive Analyse

Sexual behaviour, desire and psychosexual experience in gynephilic and androphilic trans women : a cross-sectional multi-centre study

Clinical relevance of collagen protein degradation markers c3m and c4m in the serum of breast cancer patients treated with neoadjuvant therapy in the geparquinto trial

Zusätzlicher Nutzen einer Ganzhirnbestrahlung nach chirurgischer Resektion bzw. stereotaktischer Radiotherapie von Hirnmetastasen bei Patientinnen mit Mammakarzinom

Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study

Update Breast Cancer 2018 (Part 4) – Genomics, Individualized Medicine and Immune Therapies – in the Middle of a New Era: Treatment Strategies for Advanced Breast Cancer

Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study

Nukleäre p53 Akkumulation : klinische Relevanz und Interaktion mit anderen etablierten und potentiellen Prognose-Parametern beim Mammakarzinom

Update breast cancer 2018 (part 4) – genomics, individualized medicine and immune therapies – in the middle of a new era : treatment strategies for advanced breast cancer

Update Mammakarzinom 2018 (Teil 4) – Genomforschung, individualisierte Medizin und Immuntherapien – mitten in einer neuen Ära : Therapie des fortgeschrittenen Mammakarzinoms

Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus : Spectrum of Opinion of German Specialists at the 15th International St. Gallen Breast Cancer Conference (Vienna 2017)

AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2017

Stellenwert der Präparatradiographie in der brusterhaltenden Therapie des Duktalen Carcinoma in Situ (DCIS)

Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer – results from the HER-OS patient registry

Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer – results from the HER-OS patient registry

Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers

AGO Recommendations for Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2013

AGO Recommendations for Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2013

Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers

Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study

Relevance of activated leukocyte cell adhesion molecule (ALCAM) in tumor tissue and sera of cervical cancer patients

Relevance of PTEN loss in brain metastasis formation in breast cancer patients

A clinically relevant gene signature in triple negative and basal-like breast cancer

Prognostic impact of circulating tumor cells assessed with the CellSearch System and AdnaTest Breast in metastatic breast cancer patients: the DETECT study

Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer

A clinically relevant gene signature in triple negative and basal-like breast cancer

Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer